Interactions between proteins play a critical role in cell function and dysfunction. Such interactions can be identified by phage display 1,2 and the yeast two-hybrid system 3-6 , as well as by biochemical methods. The identification of a protein-protein interaction is, however, only the first step. Modulation of the interaction is necessary to produce true insight into its biological purpose. Blocking particular protein-protein interactions with specific ligands would enable exquisite control of cellular processes and provide potential leads for novel chemotherapeutic agents 7 .
Interactions between proteins play a critical role in cell function and dysfunction. Such interactions can be identified by phage display 1, 2 and the yeast two-hybrid system [3] [4] [5] [6] , as well as by biochemical methods. The identification of a protein-protein interaction is, however, only the first step. Modulation of the interaction is necessary to produce true insight into its biological purpose. Blocking particular protein-protein interactions with specific ligands would enable exquisite control of cellular processes and provide potential leads for novel chemotherapeutic agents 7 .
HIV-1 protease is critical to viral maturation and infectivity 8, 9 , and is a primary target in AIDS chemotherapy [10] [11] [12] . To treat AIDS, attempts have been made to inactivate the protease using active sitedirected inhibitors. This strategy has led to the appearance of numerous HIV strains with drug-resistant proteases 10, 13 . The prevalence of these resistant strains, along with the toxicity of existing drugs, underscores the need for an alternative approach.
Disrupting the quaternary structure of HIV-1 protease is an orthogonal means of inactivating the enzyme [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] . HIV-1 protease is composed of two identical 99-residue subunits 26 . Dissociation of the active, dimeric form of the enzyme results in the complete loss of catalytic activity. We sought to identify new molecules that interfere with the dimerization of HIV-1 protease. In doing so, we were able to develop a genetic selection for dissociative inhibitors of virtually any designated protein-protein interaction.
Results and discussion Strategy. Our approach takes advantage of the properties of the repressor protein from bacteriophage λ (ref. 27 ). The lambda repressor protein (cI) binds to its operator DNA as a homodimer. Each monomer has two distinct domains 28 , an N-terminal DNAbinding domain and a C-terminal dimerization domain. The role of the C-terminal domain of cI can be fulfilled by another protein [29] [30] [31] [32] [33] [34] [35] or a peptide 36, 37 .
We fused a variant protease (D25N) to the N-terminal DNAbinding domain of cI (NcI; residues 1-131) to create a hybrid repressor (NcI-PR). A dimer of the D25N variant is indistinguishable from the native protease, except for its lack of catalytic activity 38 . Because NcI alone is not capable of binding DNA in vivo, the function of NcI-PR relies on dimerization being mediated by its protease domain. We constructed the selection module λP R -lacZ-tet in a reporter plasmid that also directs the production of NcI-PR (Fig. 1) . We found that NcI-PR and a related hybrid protein (NcI-dPR2) do efficiently repress the transcription of the lacZ and tet genes, which are under control of the λP R promoter (Table 1) .
We constructed a library of 5 × 10 8 peptides with nine random residues fused to the solvent-exposed C terminus of Escherichia coli thioredoxin (Trx). Trx and the nonapeptide library were separated by a SG 3 tetrapeptide spacer. The genetic encoding of this library allows for its facile creation, maintenance, and reproduction 39 . We chose not to constrain the peptides 5, 6, 40 so as to avoid an a priori conformational bias that could limit the number of effective inhibitors. When a cell is transformed with the reporter plasmid, NcI-PR represses the transcription of the reporter genes and the transformant shows a LacZ -Tet S phenotype. Upon cotransformation with the peptide library plasmid (Fig. 1) , cells that bear dissociative peptides should show a LacZ + Tet R phenotype, propagating on solid medium containing tetracycline and forming blue colonies. The stringency of selection can be tuned by changing the tetracycline concentration (between 10 and 40 µg ml -1 ). To screen the library, we transformed bacteria sequentially with the library plasmid and the reporter plasmid, and then selected for tet R cells (at 20 µg ml -1 tetracycline).
Approximately 300 of the 3 × 10 8 cotransformants showed a LacZ + Tet R phenotype, a selection of 1 in 10 6 . This low frequency is surprising. Apparently, disrupting the interaction between two proteins, even small ones such as HIV-1 protease monomers, is difficult. The formidable challenge of identifying inhibitors of a proteinprotein interaction highlights the need for a facile assay that can sift rapidly through large (>10 8 -member) libraries for active molecules. Our approach meets these criteria. In contrast, genetic selections based on eukaryotic cells (such as the yeast two-hybrid system) are impaired by low transformation efficiencies and cannot reliably identify rare (1 in 10 6 ) events.
Genetic selection for dissociative inhibitors of designated protein-protein interactions
Elimination of false positives. False positive results are common to genetic selections and screens that rely on the transcriptional control of reporter genes. A likely false positive result in our system is a Trx-peptide fusion that interferes with the interaction between λO R1 and NcI, and thus results in a LacZ + Tet R phenotype regardless of the integrity of the protease dimer. We used a gel retardation assay to screen 120 positive isolates from the genetic selection for the ability to interfere with the λO R1 -NcI interaction by using a gel retardation assay. Specifically, we mixed lysates from LacZ + Tet R cells with wild-type cI protein and fluorescein-labeled λO R1 DNA, and subjected the mixture to electrophoresis in a polyacrylamide gel. False positives (one-fifth of the cotransformants with LacZ + Tet R phenotype) cause the shifted band to disappear ( Fig. 2A) by interfering with the protein-DNA interaction. Additional gel retardation assays showed that the false positives bind to NcI rather than λO R1 (data not shown).
High-throughput ELISA.
A molecule that disrupts a dimer would likely have affinity for the interfacial surface of its constituent monomers. We developed a highthroughput screening method to test the ability of Trx-peptide fusions to bind to monomeric protease. Specifically, we covalently immobilized either urea-denatured or native protease on the surface of a maleimideactivated 96-well plate through its two reactive cysteine residues (Cys 67 and Cys 95). Free monomers were removed from immobilized monomers by extensive washing following the alkylation reaction. Positive isolates from the gel retardation assay were tested for the ability to bind to the protease monomer. Bound Trx-peptide fusions were identified by an enzyme-linked immunosorbent assay (ELISA) using fluorescein diphosphate (FDP) as a substrate for the alkaline phosphatase conjugate (Fig. 2B) . The affinity of a peptide for the protease should be related to the intensity of the ELISA signal. We identified the nine isolates that produced the strongest signal, and determined the sequence of their encoded peptides. Using immobilized urea-denatured or native protease gave similar results (data not shown).
Analysis of true positives. The sequences of the most effective peptides fall into three groups (Fig. 2C) . A common feature in all three groups is the abundance of nonpolar residues, especially valine, alanine, and glycine. This overall composition is similar to that of the dimer interface of HIV-1 protease, which consists largely of an anti-parallel β-sheet composed of the four N-and C-terminal segments of the dimer: P 1 Q 2 I 3 T 4 and T 96 L 97 N 98 F 99 , respectively 26 . The lack of strong similarity among the nine sequences is not surprising, because the clones are from a single round of selection in vivo rather than multiple rounds of selection in vitro (in which positive clones are enriched in each round 1, 2 ). Known peptide inhibitors of HIV-1 protease dimerization are based verbatim on the dimeric interface [14] [15] [16] [17] [18] 20, 21, [23] [24] [25] . In contrast, the sequences from positive isolates (Fig. 2C) do not imitate the protease, and hence are new leads for chemotherapeutic agents.
Dissociative inhibitors of multisubunit enzymes differ in their mechanism of action from that of traditional enzyme inhibitors 7 . An in vitro analysis of inhibition enabled us to distinguish between competitive, uncompetitive, and dissociative inhibition of HIV-1 protease. We synthesized a peptide (pep52) corresponding to a Trx-peptide fusion that gave a strong signal in the ELISA. We found that pep52 gives a series of parallel lines in a Zhang-Poorman plot, which is diagnostic of pure dissociative inhibition 15 . The dissociative inhibition constant (K id ) is 32 µM (Fig. 3A) . We also used an independent biochemical method to test the ability of pep52 to disassemble the protease dimer. According to analytical gel filtration chromatography, pep52 causes the dimer to dissociate into monomers (Fig. 3B) . The broad peak of the monomer indicates a lack of compact structure 41, 42 , which could have the therapeutic benefit of making the enzyme vulnerable to proteolysis in vivo.
The peptides identified by our approach are likely to bind specifically to HIV-1 protease. First, the ELISA and gel retardation assay for false positives demand that the peptides interact strongly with monomeric protease but not NcI. Second, the peptides do not impair the growth of Escherichia coli cells (data not shown), indicating a lack of affinity for critical cellular proteins and protein complexes, such as those involved in DNA replication and transcription.
Inhibitor dimers. Multivalent display could be a simple way to increase the potency of a dissociative inhibitor. Creating a homod-RESEARCH ARTICLES 29 . Susceptibility to tetracycline (10 µg ml -1 ) and β-galactosidase activity were measured as indicators of binding to λO R1 29,30 . Repression is calculated as follows: 1 -(β-galactosidase activity with repressor / β-galactosidase activity without repressor).
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imeric inhibitor by tethering the peptide in a head-to-head or a tailto-tail fashion would present the peptide with increased valency 21, 24 . Accordingly, we prepared a dimeric peptide (dim52) by adding a cysteine residue to the C terminus of pep52 and crosslinking with a homobifunctional reagent (Fig. 3C ). An in vitro analysis revealed that dim52 is a potent dissociative inhibitor with a K id of 780 nM (Fig. 3D) , which is 40-fold less than that of the monomer. Use of an optimized crosslinker 21, 23 or conformational constraint 24 could decrease K id further. AIDS chemotheraphy. Our approach is well-suited for developing new antiviral chemotherapeutic agents. Viruses have small genomes, conserving material by using multimeric proteins. Subunit interfaces in the many multimeric viral enzymes and the viral capsid are ideal targets for disruption. As an added benefit, dissociative inhibitors could intercept a viral polyprotein precursor before its processing and assembly leads to any function 20 .
The high rate of viral replication and low fidelity of HIV reverse transcriptase have resulted in the emergence of HIV strains with resistance against drugs, including protease inhibitors 43, 44 . To overcome resistance to individual drugs, combination therapy has been practiced in which multiple inhibitors with different antiviral mechanisms are used simultaneously to treat AIDS 13, 45, 46 . Recent evidence suggests, however, that the conventional triple-drug therapy can fail because of the emergence of HIV isolates with cross-resistance against different drugs 47, 48 . Further, some of these cross-resistant HIV strains are also resistant to new compounds in clinical trials, including protease and reverse transcriptase inhibitors 49 . To date, all inhibitors of HIV-1 protease approved for human use are peptide mimetics that bind in the active site.
Dissociative inhibitors could be less prone to drug resistance than are active site-directed inhibitors 7 . Active site-directed inhibitors rely on a few high-affinity interactions with the protease. Protease variants with a change to a single active site residue often emerge during treatment of AIDS patients with small-molecule inhibitors and can cause drug resistance 13, 45, 46 . In contrast, interactions between a dissociative inhibitor and protease monomer are likely to involve many residues encompassing a large surface area. The residues in the dimeric interface are highly conserved, even among protease variants that resist active site-directed drugs 50 . The native enzyme is unlikely to tolerate changes in these residues, which are inaccessible to solvent 26 .
The effect of a dissociative inhibitor can be catalytic. HIV-1 protease has several sites for autoproteolysis 51 . The presence of these sites and the absence of compact structure (Fig. 3B) 41, 42 make the monomer an especially good substrate for active dimers of HIV-1 protease (as well as endogenous cellular proteases). Indeed, the asymmetry of monomer elution during gel filtration chromatography in the presence of pep52 (Fig. 3B) is consistent with its proteol- 
RESEARCH ARTICLES
ysis by active dimers. It is noteworthy that proteolysis not only reduces the total number of protease molecules, but also shifts the monomer-dimer equilibrium toward the inactive monomer. Prospectus. Many biological processes rely on noncovalent interactions between proteins. The ability to interfere with specific protein-protein interactions would expedite the dissection of complex biological processes and facilitate the development of new chemotherapeutic agents. Our genetic selection (Fig. 1) , along with our in vitro screens (Fig. 2) , provides a powerful tool for the rapid identification of potent dissociative inhibitors in large combinatorial libraries. Here, we demonstrated the efficacy of our approach by identifying molecules that dissociate a homodimeric target protein (Fig. 3) . Our approach is likewise applicable to the disruption of heterodimers, as effective hydrid repressor proteins can be assembled by heterodimerization 31, 33, 37 . Finally, although we panned a peptide library, our approach can also be used to sift through a library of RNA or cell-permeable small molecules for dissociative inhibitors.
Experimental protocol
Library plasmid. A degenerate oligonucleotide, 5′-AATTTA(GGT) 3 (XYZ) 9 TA-ACCCGGCG-3′, was synthesized to encode a peptide of nine random amino acid residues. The base composition of the XYZ codons, X = A(32%)/G(39%)/C(21%)/T(8%), Y = A(27%)/G(23%)/C(25%)/T(24%), and Z = G(40%)/T(60%), was as described 52 . The XYZ codons are flanked by codons for an SG 3 spacer and ochre stop codon.
The complexity of as few as six degenerate codons (4 18 ) exceeds that of the human genome. Accordingly, producing a DNA duplex in which nine codons are degenerate presents a special problem. (For example, much diversity would be lost by simply annealing two degenerate oligonucleotides.) To overcome this problem, we used the gapped-duplex method 53 , in which a degenerate oligonucleotide is annealed to two shorter oligonucleotides that are complementary to nondegenerate termini. The gap in the duplex DNA is ultimately filled in vivo. Specifically, we prepared a gapped-duplex DNA by annealing the degenerate oligonucleotide with oligonucleotides 5′-ACCAC-CACCTA-3′ and 5′-TCGACGCCGGGTTA-3′. The 5′ and 3′ ends of the resulting duplex are compatible with EcoRI and XhoI cleavage sites, respectively. The primers were phosphorylated at their 5′ ends by using T4 polynucleotide kinase. An NdeI site was introduced at the start codon of the glutathione S-transferase (GST) gene in the pGEX-4T3 vector (Pharmacia, Uppsala, Sweden) by site-directed mutagenesis. The GST fragment was replaced with the trxA gene at the NdeI/EcoRI sites, resulting in plasmid pSH12. The phosphorylated gapped duplex was ligated to pSH12 that had been digested with EcoRI and XhoI. Electroporetic transformation of MC1061 cells with the ligated DNA yielded 5 × 10 8 initial transformants. The transformants were grown in Luria-Bertani (LB) medium containing ampicillin (100 µg ml -1 ) for 4 h at 37°C before the preparation of the library plasmid (Fig. 1B) . Analysis of the unamplified library indicated that 95% of clones carried inserts and that the nine XYZ codons were indeed random.
Reporter plasmid. DNA containing λP R , λO R1 , and a start codon was prepared from plasmid pRZ4737 (W.S. Reznikoff, University of Wisconsin-Madison) by polymerase chain reaction (PCR) using primers as follows: 5′-CTAAGCTTGTGCGTGTTGACTATTTTACCT-3′ and 5′-AGA-GAATTCCATGGACACCTCCTTAGTACATGC-3′, and inserted into the EcoRI and HindIII sites of a plasmid with the p15A origin and a chloramphenicol resistance gene. A DNA fragment of transcription terminator rrnBT 2 was amplified from pMAL-p2 (New England Biolabs, Beverly, MA) by PCR using primers 5′-CGGTCTAGAAAAACAGAATTTGCCTGG-3′ and 5′-AAAGCG-GCAGAAACGCAAAAAGGCCAT-3′, and inserted into the XbaI and NotI sites, which are downstream of the λP R regulatory sequences. The lacZ and tet genes were amplified from pMC1871 (Pharmacia) and pBR322, respectively, and inserted sequentially between the start codon and rrnBT 2 terminator using the NcoI and XbaI sites. PCR primers for the tet gene were designed so that the amplified gene contains the endogeneous ribosomal binding site, thereby allowing the polycistronic transcription of both lacZ and tet genes under the control of λP R and λO R1 . The resulting plasmid was labeled pSH20.
A DNA fragment encoding NcI was prepared from plasmid pJH391 (J.C. Hu). A DNA fragment encoding D25N HIV-1 protease was produced by site-directed mutagenesis of plasmid pET-HIVPR (J. Tang, University of Oklahoma Health Sciences Center). From these fragments, DNA directing the expression of an NcI-PR fusion protein (lacUV5-NcI-PR-stop codon) was constructed and inserted into pSH20, resulting in reporter plasmid pSH26 (Fig. 1B) .
Genetic selection. The library plasmid (1 µg) was transformed into electrocompetent MC1061 cells, yielding 3 × 10 8 transformants (or 0.06% of possible nine-residue sequences). Cells were diluted in LB containing ampicillin (100 µg ml -1 ) and grown for 3.5 h at 37°C before being prepared for electroporation. pSH26 (1 µg) was transformed into fresh library plasmid/MC1061 electrocompetent cells. The cotransformants were plated on LB agar medium containing ampicillin (100 µg ml -1 ), chloramphenicol (50 µg ml -1 ), X-Gal (75 µg ml -1 ), tetracycline (20 µg ml -1 ), and isopropyl-β-D-thiogalactoside (IPTG; 20 µM), and incubated for 24 h at 37°C until LacZ + Tet R colonies appeared. Library plasmids were rescued from those LacZ + Tet R colonies.
Cell lysates for in vitro assays. Each library plasmid rescued from a LacZ + Tet R colony was retransformed into MC1061. Each transformant was grown at 37°C in LB (2.0 ml) containing ampicillin (100 µg ml -1 ) until log phase, when IPTG (to 0.5 mM) was added. IPTG-induced cells were grown for an additional 2.5 h and harvested by centrifugation. Cells were resuspended in 30 µl of 20 mM Tris-HCl buffer (pH 8.0) containing phenylmethyl sulfonyl fluoride (PMSF; 1 mM), dithiothreitol (DTT; 0.5 mM), ethylenediamine tetraacetate (EDTA; 1 mM), and glycerol (10 % vol/vol). Lysozyme (2,500 units; Epicentre Technologies, Madison, WI) was added to resuspended cells with brief vortexing, and the mixture was incubated at 25°C for 15 min for lysis to occur. After centrifugation at 18,000 g for 15 min at 4°C, the cleared lysate was recovered and kept on ice or stored frozen at -80°C.
Gel retardation assay. A fluorescein-labeled, double-stranded DNA corresponding to the λO R1 sequence was made by annealing oligonucleotides 5′-TTTACCTCTGGCGGTGATAG-3′ and 5′-(6-FAM)-CTATCACCGCCA-GAGGTAAA-(6-FAM)-3′, where 6-FAM is 6-carboxyfluorescein. cI protein was produced from E. coli strain MC1061 transformed with plasmid pFG157 (J.C. Hu). Lysates from LacZ + Tet R cells were mixed with cI protein (30 µg ml -1 ) and incubated for 20 min at 25°C in 10 mM Tris-HCl buffer (pH 8.0) containing MgCl 2 (5 mM), CaCl 2 (2 mM), bovine serum albumin (BSA; 50 µg ml -1 ), sheared salmon sperm DNA (0.2 mg ml -1 ), poly(dI-dC) (50 µg ml -1 ), DTT (1 mM), and glycerol (5% vol/vol). Fluorescein-labeled λO R1 DNA was added (to 0.5 µM), and the reaction was incubated for another 15 min at 25°C before electrophoresis in a polyacrylamide (8% wt/vol) gel in 1× TBE (Tris-boric acid-EDTA) buffer at 4°C. After electrophoresis, the gel was scanned with a Fluorimager SI System (Molecular Dynamics, Sunnyvale, CA).
ELISA. HIV-1 protease was produced from E. coli strain BL21(DE3)pLysS transformed with plasmid pET-HIVPR (J. Tang) as described 54 . Purified protease (14 µg ml -1 ) was incubated for 3 h in 0.10 M HEPES-NaOH buffer (pH 7.0) or in 0.10 M MES-NaOH buffer (pH 6.6) containing urea (6 M) in maleimide-activated plates (Pierce Chemical Co., Rockville, IL). Unreacted maleimide was blocked with cysteine. Unless otherwise noted, the plate was washed (5×) by mild vortexing at 25°C for 3 min with phosphate-buffered saline (PBS) between each of the following steps. Lysates from LacZ + Tet R cells were prepared as described above, except for the use of PBS instead of TrisHCl buffer. First, a lysate in PBS was incubated at 4°C overnight in each well. Then, anti-Trx antibody (Sigma, St. Louis, MO) in PBS containing BSA (1 mg ml -1 ) was incubated in each well at 25°C for 1 h. Finally, anti-rabbit IgG-alkaline phosphatase conjugate (Sigma) in PBS was incubated at 25°C for 1 h. The increase in the fluorescence of FDP (Molecular Probes, Eugene, OR), a phosphatase substrate 55 , was measured by scanning the plate with a Fluorimager SI System (Molecular Dynamics).
Peptide synthesis. Peptide IVQVDAEGGC (pep52) was prepared by solid-phase peptide synthesis and purified by reverse-phase high-performance liquid chromatography (RP-HPLC). The peptide and 1,6-hexane-bisvinylsulfone (Pierce) were mixed in 0.10 M sodium borate buffer (pH 8.5) and incubated at 25°C for 3 h before quenching the reaction with cysteine. The crosslinked dimer of pep52 (dim52) was purified by RP-HPLC. The identity and purity of pep52 and dim52 were ascertained by electrospray ionization mass spectrometry with a Sciex API 365 System (Perkin Elmer) and amino acid analysis with an Amino Acid Analyzer 421 (Perkin Elmer, Foster City, CA), which was also used to determine solution concentrations.
HIV-1 protease assays. A fluorogenic substrate, R-E(EDANS)-SQNYPIVQ-K(DABCYL)-R (Molecular Probes) 56 , was used to assess proteolytic activity, which was measured with a QuantaMaster1 photon-counting fluorometer (Photon Technology International, Lawrenceville, NJ) as described 57 with modifications. In the modifications, HIV-1 protease was preincubated with or without inhibitor for 30 min at 25°C in 0.10 M sodium acetate buffer (pH 4.7) containing glycerol (5% vol/vol), polyethylene glycol (PEG) 8000 (0.1% vol/vol), DTT (5 mM), EDTA (1 mM), and NaCl (0.10 M). Substrate was added to start the reaction. Data were collected for 3-5 min to obtain the initial velocity, and treated as described 15 using eq. 1:
(1)
where [E t ] is the total enzyme concentration, k is the initial rate constant, [I] is the concentration of inhibitor, K d is the equilibrium dissociation constant of the protease dimer, and K id is the inhibition constant for dissociative inhibition. If inhibition is purely dissociative, then a plot of [E t ]/√k vs √k at different [I] consists of a series of parallel lines. Kinetic and thermodynamic parameters were obtained by nonlinear least-squares regression analysis of data with SIGMAPLOT 5.0 (SPSS).
Analytical gel filtration chromatography. Pep52 (0 or 5 mM) was incubated for 30 min at 25°C in 50 mM sodium acetate buffer (pH 4.7) containing wild-type protease (2.8 µM). The mixture was loaded onto a column (22 cm × 20 mm 2 ) of Superdex 75 gel filtration resin (Pharmacia) that had been pre-equilibrated with 50 mM sodium acetate buffer (pH 4.7), and eluted with the same buffer. Absorbance at 280 nm was monitored by using the program FPLC MANAGER (Pharmacia).
